Regulatory affairs is the function that decides whether a drug, device, or biologic can legally reach patients — not by running the science, but by assembling the science into a form a health authority will accept. It sits between R&D, manufacturing, clinical, and quality, and its output is a regulatory submission: a structured dossier that argues, on the strength of evidence, that a product is safe, effective, and consistently made. When teams reach for AI to “speed up regulatory work,” they almost always mean speeding up the assembly — and that is exactly where the distinction between drafting and deciding starts to matter. The mistake we see most often is treating regulatory affairs as a documentation department. It is not. It is the function that owns the relationship with agencies like the FDA, the EMA, and the MHRA, interprets evolving guidance, and translates internal scientific reality into the specific format, claims, and traceability those agencies require. Misframing it as paperwork is what leads teams to point a large language model at a folder of study reports and expect a submission to fall out. What falls out instead is fluent prose with no defensible chain of evidence — and in a regulated environment, undefended prose is a liability, not an asset. What Does a Regulatory Affairs Team Actually Do? Strip away the org charts and the work reduces to a few durable responsibilities. A regulatory affairs team determines the regulatory strategy for a product — which markets, which pathway, which classification. It compiles and submits dossiers in the formats agencies mandate, most prominently the electronic Common Technical Document (eCTD) used across the FDA, EMA, and other ICH regions. It manages correspondence with health authorities, responds to questions and deficiency letters under hard deadlines, and maintains the product’s regulatory status across its lifecycle through variations, renewals, and safety updates. Each of those responsibilities has a different relationship to automation, which is the whole point of understanding the function before deploying tools against it. Strategy is judgment work that depends on reading agency intent. Compilation is structured, repetitive, and traceable — the part most amenable to assistance. Correspondence is deadline-driven and high-stakes, where a draft that needs heavy correction can cost more time than it saves. Lifecycle maintenance is where small errors compound silently across years. Where AI Genuinely Helps the Submission Workflow The honest version of the AI story in regulatory affairs is narrow and useful rather than broad and transformative. The eCTD format is rigidly structured — five modules, defined section hierarchies, controlled vocabularies, and strict requirements for granularity and lifecycle operations. That structure is precisely what makes targeted automation tractable. In our experience working with document-heavy regulated workflows, the durable wins cluster around assembly, consistency, and traceability rather than around generating novel scientific argument. Document automation can map source content into the correct eCTD module and section, flag missing or inconsistent metadata, and check cross-references before a submission is published. Generative models can draft routine narrative sections — clinical study report summaries, non-clinical overviews — that a regulatory professional then verifies against source. Retrieval systems can surface the relevant prior submission, the applicable guidance, or the exact wording used in an approved label far faster than manual search. These are real gains, and they are gains on throughput and error reduction, not on the substance of the regulatory argument. What none of these tools do is take ownership of the claim. A model that drafts a Module 2.5 clinical overview has not decided whether the benefit-risk argument holds; a regulatory affairs professional still has to, and still signs for it. We treat this as a hard line in every life-sciences engagement. The way AI document automation handles pharma regulatory submissions without breaking GxP is by staying inside the assembly and verification layer — never by silently becoming the source of a regulated claim. Drafting Versus Deciding: The Distinction That Governs Everything Activity Job-to-be-done AI’s role Who owns the output Regulatory strategy Choose pathway, market, classification Surface precedent and guidance Regulatory professional (judgment) Dossier compilation Assemble eCTD modules correctly Map content, check structure & metadata Tool-assisted; RA verifies Narrative drafting Summarize study evidence Draft from named sources RA author verifies every claim Authority correspondence Answer deficiencies on deadline Retrieve prior context, draft replies RA decides, signs, submits Lifecycle maintenance Keep status current via variations Detect drift, flag missing updates RA owns; tool flags Read down the “who owns the output” column and the rule becomes obvious: AI accelerates the activities, but ownership of every regulated claim stays human. This is not caution for its own sake. It is what the validation regime requires. AI systems used inside a GxP workflow are themselves computerised systems subject to validation, which means the tool that drafts your submission is in scope for the same scrutiny as the submission. Teams that skip this step discover it during inspection, which is the most expensive possible moment to learn it. Why “Just Use an LLM on the Dossier” Fails in Practice The intuition is reasonable: submissions are documents, LLMs are good at documents, therefore LLMs should produce submissions. The reasoning breaks on three points that are structural, not incidental. First, a regulatory submission is an evidence argument, not a piece of writing. Every claim must trace to a source — a study report, a batch record, a stability dataset — and that traceability is auditable. A fluent paragraph that cannot be traced back to its source is worse than no paragraph, because it creates the appearance of support where none exists. We see this pattern regularly when teams evaluate generative tooling: the output reads well and fails the traceability test. Second, the tool itself enters the regulated scope. When an AI system contributes to a GxP record, it has to be classified and validated like any other software in that environment. How you classify and validate AI/ML software under GAMP 5 determines whether the tool is usable at all — and a non-deterministic model invites validation questions that a deterministic document processor does not. The validation burden is real, and choosing the right risk-based approach, such as deciding when CSA is appropriate versus full CSV, is part of making AI deployable rather than theoretical. Third, agency expectations are still settling. Regulators are actively shaping guidance on AI use in regulated submissions, and that direction is a moving target rather than a fixed spec — treat any specific expectation as provisional and confirm against current guidance (market-direction; not an operational benchmark). Building a workflow that assumes today’s tolerance will hold tomorrow is a planning error. A Practical Readiness Checklist for AI in Regulatory Affairs Before pointing any AI tool at a submission workflow, walk this list. Each item is a place we have seen deployments stall when it was skipped. Traceability is preserved end to end. Every AI-assisted claim links back to a named source record, and that link survives into the final dossier. The tool’s regulated scope is decided. You have classified the AI system under GAMP 5 and chosen a CSA or CSV path with documented rationale. Human ownership is explicit. A named regulatory professional verifies and signs every output; the model is never the system of record for a claim. The output format is the agency’s, not the model’s. eCTD structure, granularity, and metadata are enforced by the pipeline, not left to generation. Failure modes are observable. Missing references, metadata drift, and inconsistent cross-references are flagged before publishing, not after submission. If a deployment cannot satisfy all five, it is not ready — and shipping it anyway moves the cost from now to inspection, where it is far higher. This is the same lesson that surfaces in the real cost of pharmaceutical batch failure: the cheapest defect is the one caught before it propagates. For the buyer’s-eye view of how this function operates and where AI fits the day-to-day work, the companion piece on regulatory affairs in pharma in practice covers the operational angle this guide treats structurally. Both connect to the wider life-sciences AI work we take on. FAQ What is regulatory affairs in pharma? Regulatory affairs is the function that turns a company’s scientific evidence into submissions that health authorities like the FDA, EMA, and MHRA will accept. It owns regulatory strategy, dossier compilation in formats such as the eCTD, correspondence with agencies, and the product’s regulatory status across its lifecycle. It is not a documentation department — it is the function that decides whether and how a product can legally reach patients. Can AI write regulatory submissions? AI can draft routine narrative sections and assemble documents into the correct eCTD structure, but it cannot own the regulated claim. Every claim in a submission must trace to a named source and is auditable, so a regulatory professional has to verify and sign every output. AI accelerates assembly and verification; ownership of the argument stays human. Why does an AI tool used in regulatory affairs need validation? Because an AI system that contributes to a GxP record is itself a computerised system in regulated scope. It must be classified — typically under GAMP 5 — and validated through a risk-based CSA or full CSV path, with the rigor scaled to its risk. Skipping this is usually discovered during inspection, the most expensive moment to learn it. What does AI not do in regulatory submissions? It does not decide whether a benefit-risk argument holds, choose the regulatory pathway, or become the source of record for a claim. Those are judgment activities owned by regulatory professionals. AI stays inside the assembly, retrieval, and verification layer. The open question is not whether AI belongs in regulatory affairs — it does, in the assembly layer — but how far agencies will let it move toward the claim itself as guidance matures. Until that line is fixed, the safe design is the one that keeps every regulated claim traceable to a human who signs it.
